Pliant Therapeutics Inc (PLRX)

$1.23 +0.02 (1.65%)
Market Cap 74.35M
Revenue (ttm) 0.00
Net Income (ttm) -210.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 267,100
Avg Vol 1,287,138
Day's Range N/A - N/A
Shares Out 61.45M
Stochastic %K 29%
Beta 1.29
Analysts Hold
Price Target $2.78

Company Profile

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonal...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6770
Address:
331 Oyster Point Boulevard, South San Francisco, United States
SuperGreenToday
SuperGreenToday Dec. 24 at 4:33 PM
$PLRX Share Price: $1.22 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.15 – $0.19 Potential Upside: 71% ROI Time to Expiration: 204 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 22 at 3:19 PM
$PLRX has been under accumulation 1.2-1.30 .... Potential January popper.... These low prices won't last much longer.
0 · Reply
Old_Bag
Old_Bag Dec. 18 at 11:27 PM
$PLRX $VTGN That fucking clown blocked me for calling out his bs btw
0 · Reply
stabbed
stabbed Dec. 18 at 10:01 PM
$PLRX $VTGN
1 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 18 at 9:52 PM
Tax-loss selling this month is contributing to downward pressure on stock prices, especially in small-cap stocks, resulting in exaggerated declines. Many small-cap biotech names are now trading at bargain levels. For example, $PLRX has a net cash value of ~$3 per share, while $VTGN has ~$1.56 in net cash. The January effect could help many of these oversold stocks rebound as the selling pressure eases. Based on my experience, these prices won't stay at these levels for long. The market tends to adjust very quickly.
0 · Reply
MasterSniper
MasterSniper Dec. 17 at 3:28 PM
$PLRX $RXRX looking real good here for swings 💚💚💚 NFA DYODD
0 · Reply
R0MER0
R0MER0 Dec. 17 at 3:03 PM
$PLRX $OCG those 2 are going to make me good money 💰
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 16 at 11:09 PM
$PLRX Another reason to keep it in your radar. OI for Jan16 2026 remains very high. Price targets also still well abv current price. At some point the stock will adjust its price to near its net cash per share, thats currently $3.00–$3.30
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 16 at 10:13 PM
$PLRX Form 8-K https://ir.pliantrx.com/node/10511/html "On December 10, 2025, Pliant Therapeutics, Inc.’s (the “Company”) Board of Directors (the “Board”) appointed Minnie Kuo as Chief Operating Officer, effective immediately". Interesting news for a company that is currently trading at a significant discount to its net cash
0 · Reply
sandman7473
sandman7473 Dec. 16 at 9:07 PM
$PLRX this one is so ripe for an MA or BO. Just my opinion.
0 · Reply
Latest News on PLRX
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Dec 4, 2025, 1:53 PM EST - 20 days ago

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

MRK

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Dec 4, 2025, 7:30 AM EST - 21 days ago

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Dec 1, 2025, 8:30 AM EST - 24 days ago

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 6 weeks ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Pliant Therapeutics Provides Update on BEACON-IPF

Jun 27, 2025, 4:05 PM EDT - 6 months ago

Pliant Therapeutics Provides Update on BEACON-IPF

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025, 4:03 PM EDT - 7 months ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 8 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

May 1, 2025, 4:05 PM EDT - 8 months ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Apr 7, 2025, 4:05 PM EDT - 9 months ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Pliant Therapeutics: An Activist On Deck

Apr 3, 2025, 12:22 PM EDT - 9 months ago

Pliant Therapeutics: An Activist On Deck

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Mar 17, 2025, 8:00 AM EDT - 10 months ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Mar 13, 2025, 11:04 AM EDT - 10 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 13, 2025, 7:20 AM EDT - 10 months ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 4:05 PM EST - 10 months ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Mar 3, 2025, 1:32 PM EST - 10 months ago

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Mar 3, 2025, 9:27 AM EST - 10 months ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Mar 2, 2025, 11:00 AM EST - 10 months ago

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Feb 27, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Feb 26, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Feb 25, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Feb 24, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 10 months ago

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

Feb 21, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 20, 2025, 3:39 PM EST - 10 months ago

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Feb 20, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation

Feb 19, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation

Feb 18, 2025, 10:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation

SuperGreenToday
SuperGreenToday Dec. 24 at 4:33 PM
$PLRX Share Price: $1.22 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.15 – $0.19 Potential Upside: 71% ROI Time to Expiration: 204 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 22 at 3:19 PM
$PLRX has been under accumulation 1.2-1.30 .... Potential January popper.... These low prices won't last much longer.
0 · Reply
Old_Bag
Old_Bag Dec. 18 at 11:27 PM
$PLRX $VTGN That fucking clown blocked me for calling out his bs btw
0 · Reply
stabbed
stabbed Dec. 18 at 10:01 PM
$PLRX $VTGN
1 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 18 at 9:52 PM
Tax-loss selling this month is contributing to downward pressure on stock prices, especially in small-cap stocks, resulting in exaggerated declines. Many small-cap biotech names are now trading at bargain levels. For example, $PLRX has a net cash value of ~$3 per share, while $VTGN has ~$1.56 in net cash. The January effect could help many of these oversold stocks rebound as the selling pressure eases. Based on my experience, these prices won't stay at these levels for long. The market tends to adjust very quickly.
0 · Reply
MasterSniper
MasterSniper Dec. 17 at 3:28 PM
$PLRX $RXRX looking real good here for swings 💚💚💚 NFA DYODD
0 · Reply
R0MER0
R0MER0 Dec. 17 at 3:03 PM
$PLRX $OCG those 2 are going to make me good money 💰
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 16 at 11:09 PM
$PLRX Another reason to keep it in your radar. OI for Jan16 2026 remains very high. Price targets also still well abv current price. At some point the stock will adjust its price to near its net cash per share, thats currently $3.00–$3.30
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 16 at 10:13 PM
$PLRX Form 8-K https://ir.pliantrx.com/node/10511/html "On December 10, 2025, Pliant Therapeutics, Inc.’s (the “Company”) Board of Directors (the “Board”) appointed Minnie Kuo as Chief Operating Officer, effective immediately". Interesting news for a company that is currently trading at a significant discount to its net cash
0 · Reply
sandman7473
sandman7473 Dec. 16 at 9:07 PM
$PLRX this one is so ripe for an MA or BO. Just my opinion.
0 · Reply
ItTakesItAll
ItTakesItAll Dec. 16 at 8:46 PM
$PLRX December is a good month for me with dozens of stocks going 100%+ and beyond. Many calls up there looking great along with this one. INST own the float pretty much and is totally oversold, imho, will see how this one goes.
0 · Reply
ItTakesItAll
ItTakesItAll Dec. 16 at 6:51 PM
$BEAT 185%+ 1.21-3.49🎈 beauty!! $PLRX is going that way, imho.
0 · Reply
R0MER0
R0MER0 Dec. 16 at 6:12 PM
$PLRX 👀👀👀👀👀🍿🍿
0 · Reply
elmono
elmono Dec. 16 at 6:04 PM
$PLRX still wondering why this is so dirt cheap
0 · Reply
R0MER0
R0MER0 Dec. 16 at 5:16 PM
$PLRX add some there
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 16 at 3:38 PM
$PLRX 🤔 over 1.30 can run hard imho .... as i said yest, this name is dirt CHEAP !!
2 · Reply
sandman7473
sandman7473 Dec. 15 at 10:01 PM
$PLRX bot more
0 · Reply
ItTakesItAll
ItTakesItAll Dec. 15 at 8:26 PM
$PLRX Adding, little by little, 1.10-1.20s, oversold, undervalued, imho.
0 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 15 at 8:08 PM
$PLRX as i mentioned previously, this stock is trading at bargain prices from a fundamental standpoint with strong institution names holding big stakes.
2 · Reply
ACInvestorBlog
ACInvestorBlog Dec. 15 at 6:58 PM
Did anyone analyse the price-to-cash ratio of $PLRX and the institutions who own the stock ? The price-to-cash ratio for PLRX remains highly attractive. Net cash per share is around $4.5 per share. With the stock near the bottom of the base i took a new long swing position. Tang Capital and Point72 here :wink:
1 · Reply
TalkMarkets
TalkMarkets Dec. 14 at 3:50 PM
6 Interesting Tax Selling Stocks For A Possible January Bounce $NFE $PLRX $SEAT $ATYR https://talkmarkets.com/content/stocks--equities/6-interesting-tax-selling-stocks-for-a-possible-january-bounce?post=544579
0 · Reply
Armencho
Armencho Dec. 11 at 6:08 PM
$PLRX why wax down stupid people selling for big losses
0 · Reply